Breaking News Instant updates and real-time market news.

TWTR

Twitter

$27.00

0.2 (0.75%)

06:14
10/12/18
10/12
06:14
10/12/18
06:14

Twitter upgraded to Hold from Sell at Pivotal Research

Pivotal Research analyst Brian Wieser upgraded Twitter to Hold from Sell while lowering his price target for the shares to $24 from $26. The analyst cites valuation for the upgrade following the recent selloff in the stock.

  • 07

    Nov

TWTR Twitter
$27.00

0.2 (0.75%)

09/18/18
JPMS
09/18/18
NO CHANGE
Target $195
JPMS
Overweight
JPMorgan cuts estimates for Facebook, drops price target to $195
JPMorgan analyst Doug Anmuth lowered his 2019 and 2020 earnings estimates for Facebook (FB) by 5%-6% on the company's bigger investment increases over the next couple years, which he does not believe are fully captured in consensus estimates. The analyst says Facebook remains the most controversial company in his Internet coverage universe. The company is in transition as it pushes Stories more prominently on the core platform and rolls out stronger privacy tools for users. Even with Facebook suggesting it could reach mid-30%'s operating margins in a few or several years, investments in 2019 could be larger than anticipated in consensus estimates, Anmuth tells investors in a research note. The analyst also cut his price target for the shares to $195 from $205. However, he keeps an Overweight rating on the shares. Anmuth's top overall Internet picks are Amazon.com (AMZN), Twitter (TWTR) and Yelp (YELP.)
10/11/18
BTIG
10/11/18
NO CHANGE
Target $30
BTIG
Sell
Square CFO resignation adds to uncertainty risk, says BTIG
BTIG analyst Mark Palmer maintained his Sell rating and $30 price target on Square (SQ) after its yesterday's announcement that CFO Sarah Friar is planning to step down at the end of the year. The analyst notes that Friar has been viewed as "serving in a role more expansive and crucial than that of a typical CFO" given the divided focus of CEO Jack Dorsey on his position as CEO of Twitter (TWTR). The analyst also maintains his view that Square's "increasing dependence on the extension of credit to its customers" has made its business model more vulnerable to credit market volatility.
10/11/18
GSCO
10/11/18
NO CHANGE
Target $11
GSCO
Buy
Snap price target lowered to $11 from $17 at Goldman Sachs
Goldman Sachs analyst Heath Terry lowered his price target for Snap (SNAP) to $11 from $17, while reiterating a Buy rating on the shares. With Snap shares down 50% since the company reported Q2 results, beyond the broader weakness in social media, the analyst believes investors are clearly focused on the impact competition is having on the company's user growth, ability to monetize, and capital needs. Terry continues to believe that a Twitter-like (TWTR) turnaround is possible, particularly as the new Android app comes out of Alpha later this quarter. However, it is unlikely that Q3 results will show any signs of that as reported DAUs decline and engagement is negatively impacted by the redesign/competition, he contends.
10/11/18
10/11/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN UPGRADES LUMENTUM AFTER SELLOFF: JPMorgan analyst Samik Chatterjee upgraded Lumentum (LITE) to Overweight from Neutral with an unchanged price target of $80. The 19% stock decline from the highs in late August, driven by concerns relative to U.S.-China trade, over-appreciates the "modest risks" for Lumentum, Chatterjee said. He believes this creates an "attractive buying opportunity" to capitalize on the near-term improvement in the earnings outlook. GOLDMAN CUTS HUNTINGTON TO SELL: Goldman Sachs analyst Noah Poponak downgraded Huntington Ingalls Industries (HII) to Sell from Neutral and lowered his price target for the shares to $208 from $220. Poponak said Huntington is now the most expensive stock in his Defense coverage on economic, price-to-earnings and free cash flow yield. The analyst believes the stock could underperform Defense peers in the medium-term given the valuation. JEFFRIES STARTS HERBALIFE WITH A BUY: Jefferies analyst Akshay Jagdale started Herbalife Nutrition (HLF) with a Buy rating and $65 price target. After a period of "muted growth," Herbalife's sales looked poised to accelerate to a more normalized range of 5%-9%, Jagdale believes. He thinks the company should be able to grow at least in line with its total addressable market growth rate of 6%. This, coupled with margin expansion and accretive free cash flow usage, should drive "significant" earnings upside and support a "growth company valuation," Jagdale said. JPMORGAN RAISES PRICE TARGET ON NY TIMES: JPMorgan analyst Alexia Quadrani raised her price target for New York Times (NYT) to $32 and reiterated an Overweight rating on the shares ahead of the company's Q3 results. The analyst said that while quarterly subscriber growth may continue to be volatile, the company's longer-term trends are positive. She expects New York Times' growth to "remain at elevated levels for the foreseeable future." SNAP PRICE TARGET CUT AT GOLDMAN SACHS: Goldman Sachs analyst Heath Terry lowered his price target for Snap (SNAP) to $11 from $17, while reiterating a Buy rating on the shares. With Snap shares down 50% since the company reported Q2 results, beyond the broader weakness in social media, the analyst believes investors are clearly focused on the impact competition is having on the company's user growth, ability to monetize, and capital needs. Terry continues to believe that a Twitter-like (TWTR) turnaround is possible, particularly as the new Android app comes out of Alpha later this quarter. However, it is unlikely that Q3 results will show any signs of that as reported DAUs decline and engagement is negatively impacted by the redesign/competition, he said.

TODAY'S FREE FLY STORIES

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

, INCY

Incyte

$66.09

1.66 (2.58%)

18:44
10/21/18
10/21
18:44
10/21/18
18:44
Hot Stocks
Eli Lilly, Incyte shares updated safety analysis of Olumiant in active RA »

Eli Lilly (LLY) and…

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

INCY

Incyte

$66.09

1.66 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

WAL

Western Alliance

$49.42

-4.11 (-7.68%)

18:36
10/21/18
10/21
18:36
10/21/18
18:36
Recommendations
Western Alliance analyst commentary  »

Western Alliance should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

FFBC

First Financial Bancorp

$24.91

-2.51 (-9.15%)

18:32
10/21/18
10/21
18:32
10/21/18
18:32
Upgrade
First Financial Bancorp rating change  »

First Financial upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

HRZN

Horizon Technology

$11.45

0.06 (0.53%)

18:29
10/21/18
10/21
18:29
10/21/18
18:29
Downgrade
Horizon Technology rating change  »

Horizon Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

NCNA

NuCana

$18.90

1.9 (11.18%)

18:25
10/21/18
10/21
18:25
10/21/18
18:25
Recommendations
NuCana analyst commentary  »

NuCana updated Phase Ib…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

CBNK

Capital Bancorp

$12.75

(0.00%)

18:25
10/21/18
10/21
18:25
10/21/18
18:25
Initiation
Capital Bancorp initiated  »

Capital Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.19

0.005 (0.04%)

, GOLD

Randgold

$81.91

0.23 (0.28%)

18:03
10/21/18
10/21
18:03
10/21/18
18:03
Hot Stocks
ISS recommends Barrick, Randgold shareholders vote in favor of merger »

Barrick Gold (ABX)…

ABX

Barrick Gold

$13.19

0.005 (0.04%)

GOLD

Randgold

$81.91

0.23 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$140.06

0.74 (0.53%)

, IBM

IBM

$129.16

-1.36 (-1.04%)

17:45
10/21/18
10/21
17:45
10/21/18
17:45
Hot Stocks
Visa readies B2B Connect for market »

Visa (V) announced new…

V

Visa

$140.06

0.74 (0.53%)

IBM

IBM

$129.16

-1.36 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 28

    Oct

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 29

    Jan

  • 03

    Mar

T

AT&T

$32.86

0.36 (1.11%)

, CMCSA

Comcast

$35.97

0.02 (0.06%)

17:42
10/21/18
10/21
17:42
10/21/18
17:42
Hot Stocks
Box Office Battle: 'Halloween' breaks records with scary $77.5M »

Comcast (CMCSA)…

T

AT&T

$32.86

0.36 (1.11%)

CMCSA

Comcast

$35.97

0.02 (0.06%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.66

-0.38 (-0.68%)

FOX

21st Century Fox

$45.51

0.05 (0.11%)

FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

LGF.A

Lionsgate

$22.20

(0.00%)

DIS

Disney

$118.81

2.55 (2.19%)

VIAB

Viacom

$33.24

-0.49 (-1.45%)

VIA

Viacom

$36.75

-0.48 (-1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 14

    Nov

  • 14

    Nov

FOX

21st Century Fox

$45.51

0.05 (0.11%)

, FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

17:24
10/21/18
10/21
17:24
10/21/18
17:24
Periodicals
AMC's Collier named next leader of Fox Network, NY Times reports »

Fox (FOXA) will turn to…

FOX

21st Century Fox

$45.51

0.05 (0.11%)

FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

VLKAY

Volkswagen

$0.00

(0.00%)

17:04
10/21/18
10/21
17:04
10/21/18
17:04
Periodicals
Audi electric SUV facing delay due to software bug, Reuters reports »

Audi's first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$34.66

-0.61 (-1.73%)

17:00
10/21/18
10/21
17:00
10/21/18
17:00
Periodicals
Blackstone to acquire Ulterra for $700M, Reuters reports »

Blackstone has agreed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

, KKR

KKR

$24.22

-0.45 (-1.82%)

16:56
10/21/18
10/21
16:56
10/21/18
16:56
Periodicals
Fiat agrees to sell Magneti Marelli to KKR's Calsonic, Bloomberg says »

Fiat Chrysler (FCAU) has…

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

KKR

KKR

$24.22

-0.45 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 30

    Oct

MRK

Merck

$72.34

0.12 (0.17%)

, AZN

AstraZeneca

$39.21

0.25 (0.64%)

16:40
10/21/18
10/21
16:40
10/21/18
16:40
Hot Stocks
Merck, AstraZeneca announce detailed results from Phase 3 SOLO-1 trial »

AstraZeneca (AZN) and…

MRK

Merck

$72.34

0.12 (0.17%)

AZN

AstraZeneca

$39.21

0.25 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 11

    Jan

  • 16

    Feb

VAR

Varian Medical

$104.25

-1.575 (-1.49%)

16:31
10/21/18
10/21
16:31
10/21/18
16:31
Hot Stocks
Varian unveils new Bravos afterloader system for brachytherapy treatments »

Varian announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.